CTSG is considered a potential immune-related biomarker in OSCC, involved in host immune defense, tumor angiogenesis, and metastasis 48-50, and has been targeted for immunotherapy in acute myeloid leukemia (AML) 51. Here, CTSG is linked to acute myeloid leukemia.